Dr. Mikkilineni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Summary
- I am an oncologist who focuses on conducting cellular therapy clinical trials for multiple myeloma.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2013 - 2016
Tulane University School of MedicineClass of 2013
Certifications & Licensure
CA State Medical License 2022 - 2026
MD State Medical License 2016 - 2023
PA State Medical License 2013 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CCF-ASCO Young Investigator Award ASCO; Funded by NIH, 2019
- Clinical Training Research Institute American Society of Hematology, 2018
Clinical Trials
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Start of enrollment: 2010 Aug 04
- Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies Start of enrollment: 2015 Sep 24
- T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies Start of enrollment: 2016 Jan 21
- Join now to see all
Publications & Presentations
PubMed
- 49 citationsMCT1 in Invasive Ductal Carcinoma: Monocarboxylate Metabolism and Aggressive Breast Cancer.Jennifer Johnson, Paolo Cotzia, Roberto Fratamico, Lekha Mikkilineni, Jason Chen
Frontiers in Cell and Developmental Biology. 2017-04-03 - 15 citationsThe impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.Aiman J Faruqi, John A Ligon, Paul Borgman, Seth M Steinberg, Toni Foley
Blood Advances. 2022-12-13 - 183 citationsSafety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphomaJennifer N. Brudno, Norris Lam, Danielle Vanasse, Yueh-wei Shen, Jeremy J. Rose
Nature Medicine. 2020-01-20
Lectures
- Infectious Complications Associated with CAR T-Cell Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
